Journal
CURRENT MEDICINAL CHEMISTRY
Volume 26, Issue 37, Pages 6786-6796Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867325666181112091700
Keywords
Isoliquiritigenin; antitumor; breast cancer; mechanisms; signaling pathway; formulation
Funding
- National Undergraduate Innovation Program
- National Natural Science Foundation of China [J1210026]
Ask authors/readers for more resources
Isoliquiritigenin (2',4',4-trihydroxychalcone, ISL) is one of the most important chalcone compounds which is mainly derived from licorice root and many other plants. It exhibits a remarkable range of potent biological and pharmacological activities such as antioxi-dative, antitumor, antiaging, anti-inflammatory, anti-diabetic activities, etc. Numerous research teams have demonstrated that ISL posseses the ability to carry out antigrowth and proliferation in various cancer cells in vitro and in vivo. Meanwhile, the underlying mechanisms of ISL that inhibit cancer cell proliferation have not been well explored. However, the poor bioavailability and low water-soluble limit its clinical application. This review aims at providing a comprehensive overview of the pharmacology antitumor activity of ISL and its mechanisms in different malignancy especially in breast cancer cell line and summarize developments of formulation utilized to overcome the barrier between its delivery characteristics and application in clinics over the past 20 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available